Ellicott City, MD – SCRS and Eli Lilly & Company today announced a Site Engagement Partnership, which allows for significant involvement and increasing direct communication with the sites. Through this partnership, Lilly brings their commitment to excellence to site development and site sustainability. “SCRS welcomes this significant partnership with Lilly, who has been a strong Global Impact Partner since 2013,” said Christine Pierre, President of SCRS. “Lilly is taking a significant leadership role in bolstering its commitment to site sustainability and continuing to connect site members with patient-centered movements in clinical research.” “Lilly greatly values our partnership with SCRS as we work together to enhance the strengths and address the challenges of conducting clinical research, particularly through the close collaborations with investigative sites. We are excited to increase our areas of SCRS global participation, further indicating our commitment to incorporating site feedback and being involved in development of solutions to achieve the mutual goal of bringing new medicines to patients,” stated Meri Kay Scott, Senior Director, Global Clinical Operations, Eli Lilly and Company. About SCRS SCRS is a global trade organization founded in 2012 which represents over 4,000 research sites in 54 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org. About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Lilly was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today the company remains true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. For more information, visit www.lilly.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.